Literature DB >> 30172789

3,4-Methylenedioxymethamphetamine, mephedrone, and β-phenylethylamine release dopamine from the cytoplasm by means of transporters and keep the concentration high and constant by blocking reuptake.

Gabriella Zsilla1, Daniella E Hegyi2, Mária Baranyi3, E Sylvester Vizi4.   

Abstract

The addiction-related behavioural effects of drugs of abuse are mediated by the mesocorticolimbic monoamine systems. We investigated the effects of 3,4-methylenedioxymethamphetamine (MDMA), mephedrone, β-phenylethylamine (β-PEA) methylphenidate (MPH) on dopamine release from mouse perfused nucleus accumbens and prefrontal cortex slices. The fractional release of [3H]-dopamine was measured at rest and in response to field stimulation. The distributions of [3H]-dopamine and its metabolites were determined using high-pressure liquid chromatography. The effect of drugs on [3H]-dopamine uptake was measured in synaptosomal P2 preparations from the frontal cortex and striatum. Similar to MDMA, mephedrone β-PEA increased the resting release of [3H]-dopamine from the nucleus accumbens and prefrontal cortex in a [Ca2+]o-independent manner, and the stimulation-evoked release was also augmented. In contrast, MPH failed to affect the resting release but potentiated the release in response to axonal activity. Similar to dopamine transporter antagonist GBR 12909, mephedrone, MDMA and MPH biphasically inhibited the [3H]-dopamine uptake. The administration of GBR 12909 and nisoxetine, or lowering the bath temperature prevented MDMA, mephedrone and β-PEA from enhancing the resting, cytoplasmic release of [3H]-dopamine, indicating the role of transporters in the release process. We conclude that amphetamine-like drugs of abuse and the trace amine β-PEA excessively increase the [Ca2+]o-independent, non-vesicular release of dopamine from the cytoplasm into the extrasynaptic space and inhibit the high-affinity transporters, thereby maintaining a high ambient, non-synaptic concentration of dopamine that may tonically control the activity of neurons equipped with dopamine receptors and is likely involved in the reinforcing effects and abusive potential of amphetamines.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dopamine; MDMA; Mephedrone; Methylphenidate; Release; β-phenylethylamine

Mesh:

Substances:

Year:  2018        PMID: 30172789     DOI: 10.1016/j.ejphar.2018.08.037

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  A review on the mitochondrial toxicity of "ecstasy" (3,4-methylenedioxymethamphetamine, MDMA).

Authors:  João Paulo Capela; Félix Dias Carvalho
Journal:  Curr Res Toxicol       Date:  2022-05-19

Review 2.  Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Authors:  Hans Emanuel Oeri
Journal:  J Psychopharmacol       Date:  2020-09-10       Impact factor: 4.153

3.  Phenethylamine is a substrate of monoamine oxidase B in the paraventricular thalamic nucleus.

Authors:  Youhei Obata; Mie Kubota-Sakashita; Takaoki Kasahara; Masafumi Mizuno; Takahiro Nemoto; Tadafumi Kato
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

4.  Contribution of analog signaling to neurotransmitter interactions and behavior: Role of transporter-mediated nonquantal dopamine release.

Authors:  Viktor Román; Rita Kedves; Kristóf Kelemen; Zsolt Némethy; Beáta Sperlágh; Balázs Lendvai; E Sylvester Vizi
Journal:  Physiol Rep       Date:  2021-11

5.  Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum.

Authors:  Laszlo G Harsing; Joseph Knoll; Ildiko Miklya
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

6.  The Pharmacological Effects of Phenylephrine are Indirect, Mediated by Noradrenaline Release from the Cytoplasm.

Authors:  Mahmoud Al-Khrasani; David A Karadi; Anna R Galambos; Beata Sperlagh; E Sylvester Vizi
Journal:  Neurochem Res       Date:  2022-08-09       Impact factor: 4.414

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.